AMGN stock news

Amgen's (AMGN) phase III study on Kyprolis in combination with dexamethasone and J&J's Darzalex meets the goal of progression-free survival for treating relapsed or refractory multiple myeloma. Read more
The Zacks Analyst Blog Highlights: Amgen, Cisco, Berkshire Hathaway, T. Rowe Price and McKesson Read more
Top Research Reports for Amgen, Cisco & Berkshire Hathaway Read more
Key highlights of the past week include regulatory and pipeline updates, and licensing deals and more. Read more
The results of a lung-cancer drug got me to go long on Amgen stock, but the larger picture is complicated….AMGN Read more
Amgen, Inc. (NASDAQ: AMGN ) shares were pulling back Monday following the presentation of new data on its investigational compound for solid tumors. Good, But Not Good Enough Amgen said in a Sunday statement that new data from the Phase 1 study of AMG 510 presented as an oral presentation at the IASLC 2019 World Conference on Lung Cancer, or WCLC, showed that out of the 13 of the evaluable patients receiving the target dose of 960mg once daily — the highest dose — seven, or 54%, achieved a partial response at one or more timepoints and six achieved stable disease. Yet the 54% response rate pales in comparison to the 100% response rate from the … Full story available on Benzinga.com Read more
Amgen shares were indicated sharply lower in pre-market trading Monday after the drugmaker presented details of a trial of its key lung cancer treatment that fell short of Wall Street forecasts….AMGN Read more
Let's check out the charts to get a sense of where prices could be headed….AMGN Read more
Data showed that 54% of the non-small cell lung cancer patients studied in the trial responded to AMG 510, a so-called KRAS inhibitor, but questions remain about the durability of the drug’s effect. Read more
Amgen (AMGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues. Read more
Regeneron (REGN) and partner Sanofi get a favorable ruling against Amgen in the ongoing litigation of Praluent. Read more
On Monday, Celgene (CELG) announced a sale of its psoriasis drug Otezla for $13.4 billion to Amgen (AMGN). This deal will be all cash and is expected to clear before the end of the year. Celgene's stock climbed 3.2% the day of the announcement and has risen another 0.5% since then. Read more
Key highlights of the past week include drug approvals, and other regulatory and pipeline news. Read more
Amgen's (AMGN) purchase of Celgene's blockbuster psoriasis drug, Otezla is likely to strengthen its position in the immunology space. Read more

Company News for Aug 27, 2019

02:07pm, Tuesday, 27'th Aug 2019
Companies in the news are: AMGN, PBI, BYND, SRCI, PDCE Read more

Proudly made at

ROCKIT